Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1993-5-11
pubmed:abstractText
Müllerian inhibiting substance (MIS), a gonadal hormone important in sexual differentiation, is high (10 to 70 ng/mL) in human male serum postnatally for several years before declining during the peripubertal period, but is undetectable in female serum until the onset of puberty. The sexually dimorphic secretion of MIS suggested possibilities for its use in several clinical settings. Thirty-one patients with intersex and gonadal anomalies from 17 institutions were therefore evaluated between 1989 and 1992 with an MIS enzyme-linked immunosorbent assay (ELISA). Serum MIS levels correlated with the presence of testicular tissue in two patients with suspected anorchia, five patients with male pseudohermaphroditism, and eight other intersex patients with undescended testes, dysgenetic gonads, or ovotestes. In these latter patients, serial MIS values were also helpful to confirm complete removal of gonadal tissue postoperatively. MIS may be a more sensitive marker for the presence of testicular tissue than serum testosterone levels, both before and after the neonatal androgen surge, and, consequently, may obviate the need for human chorionic gonadotropin stimulation in the evaluation of certain intersex disorders. In values were useful in differentiating the underlying etiology of the disorder. Four patients with undetectable levels have presumptive MIS gene mutations, while 7 others with MIS values of 2 to 45 ng/mL may have bioinactive hormone of MIS receptor defects. Finally, two young girls with ovarian granulosa cell tumors had elevated MIS values that fell from 18 to 2 ng/mL and from 6.5 to 1 ng/mL during postoperative follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0022-3468
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
439-44
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:8468660-Adolescent, pubmed-meshheading:8468660-Anti-Mullerian Hormone, pubmed-meshheading:8468660-Child, pubmed-meshheading:8468660-Child, Preschool, pubmed-meshheading:8468660-DNA Mutational Analysis, pubmed-meshheading:8468660-Disorders of Sex Development, pubmed-meshheading:8468660-Female, pubmed-meshheading:8468660-Glycoproteins, pubmed-meshheading:8468660-Gonadal Dysgenesis, pubmed-meshheading:8468660-Granulosa Cell Tumor, pubmed-meshheading:8468660-Growth Inhibitors, pubmed-meshheading:8468660-Humans, pubmed-meshheading:8468660-Infant, pubmed-meshheading:8468660-Infant, Newborn, pubmed-meshheading:8468660-Male, pubmed-meshheading:8468660-Mullerian Ducts, pubmed-meshheading:8468660-Ovarian Neoplasms, pubmed-meshheading:8468660-Testicular Hormones, pubmed-meshheading:8468660-Testosterone
pubmed:year
1993
pubmed:articleTitle
Müllerian inhibiting substance in the diagnosis and management of intersex and gonadal abnormalities.
pubmed:affiliation
Pediatric Surgical Research Laboratory, Massachusetts General Hospital, Boston 02114.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't